seitlicher Menuepunkt

seitlicher Menuepunkt


Publikationen in internationalen Fachzeitschriften

Forschungsergebnisse, die in renommierten, internationalen Journalen eingereicht und nach positiver Beurteilung von Experten publiziert wurden. (2010-2017)


  1. Pleyer L, Dohner H, Dombret H, Seymour JF, Schuh AC, Beach CL, et al. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group. International journal of molecular sciences. 2017;18(2).
  1. Pleyer L, Burgstaller S, Stauder R, Girschikofsky M, Sill H, Schlick K, et al. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol. 2016;9:39.
  2. Fridrik MA, Jaeger U, Petzer A, Willenbacher W, Keil F, Lang A, et al. Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentose Tumortherapie AGMT](NHL-14). Eur J Cancer. 2016;58:112-21.
  3. Greil R, Obrtlikova P, Smolej L, Kozak T, Steurer M, Andel J, et al. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. The Lancet Haematology. 2016;3(7):e317-29.
  4. Boll B, Goergen H, Behringer K, Brockelmann PJ, Hitz F, Kerkhoff A, et al. Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials. Blood. 2016;127(18):2189-92.
  5. Rachar V, Czejka M, Kitzmueller M, Buchner P, Lichtneckert M, Greil R, et al. Assessment of Pharmacokinetic Interaction Between Capecitabine and Cetuximab in Metastatic Colorectal Cancer Patients. Anticancer research. 2016;36(9):4715-23.
  6. Kiesewetter B, Willenbacher E, Willenbacher W, Egle A, Neumeister P, Voskova D, et al. A phase II study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). Blood. 2016.
  1. Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Ben Yehuda D, et al. Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. Haematologica. 2015;100(7):955-63.
  2. Pircher M, Mlineritsch B, Fridrik MA, Dittrich C, Lang A, Petru E, et al. Lapatinib-plus-pegylated liposomal doxorubicin in advanced HER2-positive breast cancer following trastuzumab: a phase II trial. Anticancer research. 2015;35(1):517-21.
  3. Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, et al. Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin\\\'s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet (London, England). 2015;385(9976):1418-27.
  1. Hopfinger G, Nosslinger T, Lang A, Linkesch W, Melchardt T, Weiss L, et al. Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. Annals of hematology. 2014;93(3):459-62.
  2. Pleyer L, Burgstaller S, Girschikofsky M, Linkesch W, Stauder R, Pfeilstocker M, et al. Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group. Annals of hematology. 2014;93(11):1825-38.
  3. Pleyer L, Germing U, Sperr WR, Linkesch W, Burgstaller S, Stauder R, et al. Azacitidine in CMML: matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leukemia research. 2014;38(4):475-83.
  1. Pleyer L, Stauder R, Burgstaller S, Schreder M, Tinchon C, Pfeilstocker M, et al. Azacitidine in patients with WHO-defined AML – Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. Journal of Hematology & Oncology. 2013;6(1):1-13.
  2. Kubicka S, Greil R, Andre T, Bennouna J, Sastre J, Van Cutsem E, et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2013;24(9):2342-9.
  3. Boll B, Gorgen H, Fuchs M, Pluetschow A, Eich HT, Bargetzi MJ, et al. ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(12):1522-9.
  4. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. The Lancet Oncology. 2013;14(1):29-37.
  5. Troch M, Kiesewetter B, Willenbacher W, Willenbacher E, Zebisch A, Linkesch W, et al. Rituximab plus subcutaneous cladribine in patients with extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue: a phase II study by the Arbeitsgemeinschaft Medikamentose Tumortherapie. Haematologica. 2013;98(2):264-8.
  6. Keil F, Selzer E, Berghold A, Reinisch S, Kapp KS, De Vries A, et al. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck. Eur J Cancer. 2013;49(2):352-9.
  1. Jager U, Fridrik M, Zeitlinger M, Heintel D, Hopfinger G, Burgstaller S, et al. Rituximab serum concentrations during immuno-chemotherapy of follicular lymphoma correlate with patient gender, bone marrow infiltration and clinical response. Haematologica. 2012;97(9):1431-8.
  2. Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin\\\'s lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet (London, England). 2012;379(9828):1791-9.
  3. von Tresckow B, Plutschow A, Fuchs M, Klimm B, Markova J, Lohri A, et al. Dose-intensification in early unfavorable Hodgkin\\\'s lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(9):907-13.
  1. Woll E, Greil R, Eisterer W, Bechter O, Fridrik MA, Grunberger B, et al. Oxaliplatin, irinotecan and cetuximab in advanced gastric cancer. A multicenter phase II trial (Gastric-2) of the Arbeitsgemeinschaft Medikamentose Tumortherapie (AGMT). Anticancer research. 2011;31(12):4439-43.
  2. Borchmann P, Haverkamp H, Diehl V, Cerny T, Markova J, Ho AD, et al. Eight cycles of escalated-dose BEACOPP compared with four cycles of escalated-dose BEACOPP followed by four cycles of baseline-dose BEACOPP with or without radiotherapy in patients with advanced-stage hodgkin\\\'s lymphoma: final analysis of the HD12 trial of the German Hodgkin Study Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(32):4234-42.
  1. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin\\\'s lymphoma. N Engl J Med. 2010;363(7):640-52.
  2. Eich HT, Diehl V, Gorgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin\\\'s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010;28(27):4199-206.

zurück zur Übersicht